Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RPG Life SciencesNSE:RPGLIFE -0.41%93 Return-on-Tangible-Asset is 15.67% as of Jun. 2026, which is 4% below its 10-year median of 16.26. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 93/100 and a GF Value™ of ₹2,454.63 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,009 Drug Manufacturers companies, RPG Life Sciences ranks better than 91.18% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. RPG Life Sciences's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹1,230 Mil. RPG Life Sciences's average total tangible assets for the quarter that ended in Jun. 2026 was ₹7,851 Mil. Therefore, RPG Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 15.67%.
The historical rank and industry rank for RPG Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:
NSE:RPGLIFE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.96 Med: 16.26 Max: 32.72
Current: 17.04
During the past 13 years, RPG Life Sciences's highest Return-on-Tangible-Asset was 32.72%. The lowest was 4.96%. And the median was 16.26%.
NSE:RPGLIFE's Return-on-Tangible-Asset is ranked better than 91.18% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.08
vs NSE:RPGLIFE: 17.04
RPG Life Sciences (NSE:RPGLIFE) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
RPG Life Sciences Return-on-Tangible-Asset Related Terms
RPG Life Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RPGLIFE vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 15.67% mean?
RPG Life Sciences (NSE:RPGLIFE) has a Return-on-Tangible-Asset of 15.67% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on RPG Life Sciences and its competitors. This is near median its historical median of 16.26. Over the past decade, RPG Life Sciences' Return-on-Tangible-Asset has ranged from 4.96 to 32.72. According to the industry distribution chart, RPG Life Sciences ranks #89 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is RPG Life Sciences' Return-on-Tangible-Asset too high?
RPG Life Sciences' current Return-on-Tangible-Asset of 15.67% is near median its 10-year median of 16.26. Over the past 10 years, this metric has ranged from a low of 4.96 to a high of 32.72. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.08. RPG Life Sciences' value of 15.67% is 408.8% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #89 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, RPG Life Sciences has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #89 out of 1009 companies for Return-on-Tangible-Asset. This places RPG Life Sciences in the top 9% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.08. RPG Life Sciences' value of 15.67% is 408.8% above this benchmark. Historically, RPG Life Sciences' own Return-on-Tangible-Asset has ranged from 4.96 to 32.72 over the past decade. While the company's 10-year median is 16.26 vs. the industry median of 3.08, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.08, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current Return-on-Tangible-Asset of 15.67% is 408.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current Return-on-Tangible-Asset is 15.67%, which is near median its own 10-year median of 16.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,454.63, compared to a current price of ₹2,756.80 — trading 12.3% above its estimated fair value. The current Return-on-Tangible-Asset is 15.67%, which is near median its 10-year median of 16.26 and 408.8% above the Drug Manufacturers industry median of 3.08. RPG Life Sciences' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current Return-on-Tangible-Asset is 15.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,756.80 is trading 12.3% above its estimated GF Value™ of ₹2,454.63.
GuruFocus considers RPG Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:RPGLIFE:
Return-on-Tangible-Asset: 15.67% (near median its 10-year median of 16.26)
GF Value™: ₹2,454.63 vs. price of ₹2,756.80 (12.3% above fair value)
Industry Position: 408.8% above the Drug Manufacturers median (#89 of 1009)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
93GF Score
Get the complete analysis for NSE:RPGLIFE
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
